Localized Alpha Therapy with a Focus on Tissue Preservation
Prostate cancer is one of the most common cancers in men, and while many patients respond well to initial treatment, some will experience disease recurrence. When cancer comes back (recurrent prostate cancer) after radiation therapy, treatment options can be more limited. Surgery may carry a high risk of side effects, and additional radiation is often not possible because nearby organs have already been exposed. As a result, many patients are left with few local treatment choices and so they seek to manage the disease with long-term hormone therapy that can significantly affect quality of life.
Alpha DaRT was developed to offer a new treatment alternative: a highly targeted alpha-emitter radiotherapeutic designed to treat cancer from within. By concentrating its effect inside the prostate, nearby healthy tissue, such as the urethra, bladder, and rectum – structures that are critical to urinary, bowel, and sexual function, may potentially be spared from impact. Unlike other forms of conventional radiotherapy, Alpha DaRT may also be used in low-oxygen tumors.
Potential Benefits of Alpha DaRT for Prostate Cancer
Treating recurrent prostate cancer requires careful balance between controlling the disease and preserving quality of life. Tumors that return after radiation often develop close to structures that are critical for urinary, bowel, and sexual function, and prior treatments can limit the feasibility of surgery or additional radiation. As a result, management of recurrent disease is often highly individualized, with many patients facing options that focus more on disease control than long-term local treatment.
Targeted, intratumoral therapy
designed to deliver alpha particles directly from within
Very short-range alpha particles
that focus treatment in the tumor while seeking to limit damage to nearby tissues such as the urethra, bladder, and rectum
Designed for localized recurrences near sensitive structures
where surgery or additional external radiation may be challenging or not feasible
Potential use in low-oxygen and treatment-resistant tumor
areas that respond poorly to conventional radiation
Minimally invasive, image-guided placement
using established transperineal techniques commonly used in urology
Single-procedure treatment approach
avoiding prolonged or repeated treatment courses
May offer a localized alternative to current localized treatment options
with the goal of reducing treatment-related side effects
Developed with preservation in mind
Including urinary, bowel, and sexual function, as well as overall quality of life
Delivery of Alpha DaRT to Prostate Tumors
Alpha DaRT is administered in prostate tumors using a dedicated applicator. Before treatment, CT or MRI scans are used to create a personalized treatment plan that guides the physician where to position the Alpha DaRT sources.
During the procedure, real-time ultrasound guidance and a precision grid system help the physician navigate to the target areas within the prostate. The applicator is then used to deploy the Alpha DaRT sources into the tumor and is removed once placement is complete.
After deployment, the sources release alpha particles over a very short distance, concentrating their effect within the tumor while limiting impact on nearby healthy tissue. The treatment is performed in a single session and is designed to fit smoothly into existing clinical workflows.
Frequently Asked Questions about Alpha DaRT for Prostate Cancer
Why might someone consider Alpha DaRT as a treatment for focal recurrent prostate cancer in the current treatment landscape?
For focal recurrent prostate cancer, Alpha DaRT may offer a minimally invasive alternative compared to other currently available treatment options such as surgery or conventional radiotherapy. Alpha DaRT is unique in that, as a localized treatment, it is designed to minimize side effects and exposure to critical nearby structures such as the urethra, bladder, and rectum.
How is Alpha DaRT delivered in prostate tumors?
A dedicated delivery system is used to deploy the Alpha DaRT sources into the prostate tumor under real-time trans-rectal ultrasound guidance and a precision grid system to navigate to the target areas. The sources then release alpha particles over a very short range, concentrating their effect within the tumor while limiting exposure to surrounding healthy tissue. The procedure is typically performed in a single treatment session.
Where can someone find the Alpha DaRT treatment for prostate cancer in the U.S.?
Alpha DaRT for prostate cancer is currently available primarily through clinical trials at selected medical centers in the United States.
For those who are interested in Alpha DaRT treatment for the treatment of prostate cancer can learn more by visiting www.clinicaltrials.gov or by visiting the Alpha Tau website’s clinical trials page.